Skip to content

Author

L. Fein

We have 2 of 82 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

BACKGROUND The randomised phase III OlympiA trial (NCT02032823) compared 1 year of adjuvant olaparib (oral poly-(ADP-ribose) polymerase [PARP] inhibitor) to placebo in 1,836 patients with pathogenic/likely pathogenic BRCA1 or BRCA2 (gBRCApv) germline variants and high-risk human epidermal growth factor receptor 2 (HER2...

J. Garber, D. Cameron, C. Campbell et al. · 1 citation
Open access Sep 2026

Sociodemographic and Clinicopathologic Characteristics of Patients With Invasive Breast Cancer in Latin America: The LATINA Breast Cohort (LACOG 0615/MO39485).

A substantial proportion of BC cases in LATAM are diagnosed symptomatically and at advanced stages, and late-stage presentation is associated with sociodemographic characteristics and type of health care coverage.

G. Werutsky, Cynthia Villarreal-Garza, A. Ferrigno Guajardo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.